{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:55Z","timestamp":1790398795215,"version":"4.1.0"},"reference-count":13,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/ddt.2026.01056","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T22:10:48Z","timestamp":1787091048000},"page":"357-359","source":"Crossref","is-referenced-by-count":0,"title":["Oveporexton: The first-in-class orexin receptor 2 (OX2R) agonist approved for treatment of narcolepsy type 1 (NT1)"],"prefix":"10.5582","volume":"20","author":[{"given":"Yueyi","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Bassetti CLA, Adamantidis A, Burdakov D, <i>et al<\/i>. Narcolepsy - Clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol. 2019; 15:519-539.","DOI":"10.1038\/s41582-019-0226-9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet. 2000; 355:39-40.","DOI":"10.1016\/S0140-6736(99)05582-8"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rauf R, Asif S, AlSaafeen A, Dhantapaani KG, Nadeem MM, Rao ZK, Hameed ASS, Chintharala K, Anwar MF, Cheema AAA. Orexin deficiency in narcolepsy: Molecular mechanisms, clinical phenotypes, and emerging therapeutic frontiers. Brain Behav. 2025; 15:e70984.","DOI":"10.1002\/brb3.70984"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, Vankova J, Black J, Harsh J, Bassetti C, Schrader H, Nishino S. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002; 59:1553-1562.","DOI":"10.1001\/archneur.59.10.1553"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Blattner M, Maski K. Narcolepsy and idiopathic hypersomnia. Sleep Med Clin. 2023; 18:183-199.","DOI":"10.1016\/j.jsmc.2023.01.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Longstreth WT, Jr., Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep. 2007; 30:13-26.","DOI":"10.1093\/sleep\/30.1.13"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Wang X, Xiao F, Wang Y, <i>et al<\/i>. Changed epidemiology of narcolepsy before, during, and after the 2009 H1N1 pandemic: A nationwide narcolepsy surveillance network study in mainland China, 1990-2017. Sleep. 2023; 46:zsac325..","DOI":"10.1093\/sleep\/zsac325"},{"key":"8","unstructured":"8. Chinese Society of Sleep Disorders. Chinese guidelines for diagnosis and treatment of narcolepsy (2022). Zhonghua Shen Jing Ke Za Zhi. 2022; 55:406-420 (in Chinese)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Maski K, Trotti LM, Kotagal S, Robert Auger R, Rowley JA, Hashmi SD, Watson NF. Treatment of central disorders of hypersomnolence: An American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021; 17:1881-1893.","DOI":"10.5664\/jcsm.9328"},{"key":"10","unstructured":"10. Takeda Pharmaceuticals. Takeda&apos;s ORZEYFUL (oveporexton) Approved in China as First Orexin Agonist and Only Medicine to Treat Narcolepsy Type 1. <i>https:\/\/www.takeda.com\/newsroom\/newsreleases\/2026\/orzeyful-approved-china-narcolepsy\/<\/i> (accessed August 6, 2026)."},{"key":"11","unstructured":"11. National Medical Products Administration. The National Medical Products Administration (NMPA) has granted marketing authorization for oveporexton tablets. <i>https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20260723092018174.html<\/i> (accessed August 9, 2026) (in Chinese)."},{"key":"12","unstructured":"12. Food and Drug Administration. FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms. <i>https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms<\/i> (accessed August 7, 2026)."},{"key":"13","unstructured":"13. Orzeyful Prescribing Information. (<i>https:\/\/content.takeda.com\/?contenttype=PI&amp;product=ORZ&amp;language=ENG&amp;country=USA&amp;documentnumber=1<\/i>) (accessed August 8, 2026)."}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01056\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:29:52Z","timestamp":1790396992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01056\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01056","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01056"}}